Table 2.
Summary of HSRT outcomes
| Characteristic | Patients, N (%) |
|---|---|
| Overall incidence of LMD (n = 235) | |
| Yes | 45 (19.2) |
| No | 190 (80.8) |
| Incidence of LMD for patients with only intact metastases (n = 183) | |
| Yes | 22 (12.0) |
| No | 161 (88.0) |
| Incidence of LMD for patients with postoperative cavities (n = 137) | |
| Yes | 33 (24.1) |
| No | 104 (75.9) |
| Pattern of LMD (n = 45 targets) | |
| Diffuse Classic | 12 (26.7) |
| Diffuse Nodular | 20 (44.4) |
| Focal Classic | 6 (13.3) |
| Focal Nodular | 7 (15.6) |
| Nodular | 27 (60.0) |
| Classic | 18 (40.0) |
| Overall rate of developing LMD, event rate (95% CI) | |
| 1 year after HSRT | 12% (6% to 18%) |
| 2 years after HSRT | 16% (7% to 25%) |
| Rate of LMD for patients with only intact metastases | |
| 1 year after HSRT | 6% (0% to 13%) |
| 2 years after HSRT | 10% (0% to 24%) |
| Rate of LMD for patients with postoperative cavities | |
| 1 year after HSRT | 20% (11% to 29%) |
| 2 years after HSRT | 24% (12% to 35%) |
| Death without developing LMD | 143 (60.9) |